News
Article
ePT--the Electronic Newsletter of Pharmaceutical Technology
Author(s):
Zydus Cadila, a pharmaceutical company based in Ahmedabad, Gujarat, India, will begin conducting trials for a H1N1 vaccine.
Zydus Cadila, a pharmaceutical company based in Ahmedabad, Gujarat, India, will begin conducting trials for an H1N1 vaccine following an approval by the Drug Controller General of India. The company says it is the first Indian company authorized to begin trials for the H1N1 vaccine.
The egg-based vaccine is expected to be available by April 2010. The company estimates that demand for the H1N1 vaccine in India will be 50–60 million does in the initial phase.
Zydus recently set up a vaccine technology center near its manufacturing center in Moraiya, Ahmedabad, India.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.